BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28717855)

  • 1. Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
    Okuno T; Wakabayashi M; Kato K; Shinoda M; Katayama H; Igaki H; Tsubosa Y; Kojima T; Okabe H; Kimura Y; Kawano T; Kosugi S; Toh Y; Kato H; Nakamura K; Fukuda H; Ishikura S; Ando N; Kitagawa Y;
    Int J Clin Oncol; 2017 Dec; 22(6):1042-1049. PubMed ID: 28717855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
    Shinoda M; Ando N; Kato K; Ishikura S; Kato H; Tsubosa Y; Minashi K; Okabe H; Kimura Y; Kawano T; Kosugi S; Toh Y; Nakamura K; Fukuda H;
    Cancer Sci; 2015 Apr; 106(4):407-12. PubMed ID: 25640628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glasgow Prognostic Score as a Prognostic Clinical Marker in T4 Esophageal Squamous Cell Carcinoma.
    Ohira M; Kubo N; Masuda G; Yamashita Y; Sakurai K; Toyokawa T; Tanaka H; Muguruma K; Hirakawa K
    Anticancer Res; 2015 Sep; 35(9):4897-901. PubMed ID: 26254385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
    Hamamoto Y; Mizusawa J; Katayama H; Nakamura K; Kato K; Tsubosa Y; Ishikura S; Igaki H; Shinoda M; Fukuda H; Kitagawa Y; Ando N
    Jpn J Clin Oncol; 2016 Apr; 46(4):389-92. PubMed ID: 26830150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.
    Valencia Julve J; Alonso Orduña V; Escó Barón R; López-Mata M; Méndez Villamón A
    Clin Transl Oncol; 2006 Jan; 8(1):22-30. PubMed ID: 16632436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
    Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
    Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303.
    Tsushima T; Mizusawa J; Sudo K; Honma Y; Kato K; Igaki H; Tsubosa Y; Shinoda M; Nakamura K; Fukuda H; Kitagawa Y;
    Medicine (Baltimore); 2016 May; 95(20):e3699. PubMed ID: 27196482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.
    Nishimura Y; Suzuki M; Nakamatsu K; Kanamori S; Yagyu Y; Shigeoka H
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):134-9. PubMed ID: 12007951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes from chemoradiotherapy for patients with esophageal cancer.
    Pantling AZ; Gossage JA; Mamidanna R; Newman G; Robinson A; Manifold DK; Hale PC
    Dis Esophagus; 2011 Apr; 24(3):172-6. PubMed ID: 21073614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Glasgow prognostic score in patients undergoing esophagectomy for esophageal squamous cell carcinoma.
    Feng JF; Zhao Q; Chen QX
    Saudi J Gastroenterol; 2014; 20(1):48-53. PubMed ID: 24496158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
    Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
    J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy for locally advanced esophageal cancer--a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil.
    Hsu CH; Yeh KH; Lui LT; Lee YC; Bu CF; Wang HP; Lin JT; Cheng AL
    Anticancer Res; 1999; 19(5C):4463-7. PubMed ID: 10650793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.
    Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J
    Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus.
    Ma K; Wang Q; Li T; Liu H; Liu B; Jia X; Li S; Lang J; Zhang M
    Radiat Oncol; 2014 Dec; 9():294. PubMed ID: 25515326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus.
    Takagawa R; Kunisaki C; Makino H; Kosaka T; Ono HA; Akiyama H; Shimada H
    Dis Esophagus; 2009; 22(6):482-9. PubMed ID: 19191850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
    Yokota T; Ando N; Igaki H; Shinoda M; Kato K; Mizusawa J; Katayama H; Nakamura K; Fukuda H; Kitagawa Y
    Oncology; 2015; 89(3):143-51. PubMed ID: 25895447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
    Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
    BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.